

Randomised controlled trial of the effects of fish oil emulsion in total parenteral nutrition upon tumour vascularity in patients with hepatic colorectal metastases

Submission date

17/01/2006

Recruitment status

No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date

31/07/2006

Overall study status

Completed

☐ Statistical analysis plan

☒ Results

Last Edited

18/02/2014

Condition category

Nutritional, Metabolic, Endocrine

☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mr Ashley Dennison

Contact details

Department of Surgery

Leicester General Hospital

Gwendolen Road

Leicester

United Kingdom

LE5 4PW

+44 (0)116 249 0490

ashley.dennison@dial.pipex.com

Additional identifiers

EudraCT/CTIS number

2006-000044-71

IRAS number

ClinicalTrials.gov number

NCT00942292

Secondary identifying numbers

N/A

Study information

Scientific Title**Study objectives**

The hypothesis is that intravenous feeding supplemented with omega-3 fatty acids will reduce the tumour vascularity as assessed by dynamic contrast-enhanced Magnetic Resonance Imaging (MRI) in patients with hepatic colorectal metastases.

Ethics approval required

Old ethics approval format

Ethics approval(s)

No ethics approval as of 31/07/2006.

Study design

Randomised, double-blind, controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet**Health condition(s) or problem(s) studied**

Hepatic colorectal metastases

Interventions

Intravenous feeding for three days either with or without (control) supplementation with omega-3 fatty acids.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Omega-3 fatty acids

Primary outcome measure

To assess the effect of intravenous feeding supplemented with omega-3 fatty acids on tumour vascularity as assessed by dynamic contrast enhanced MRI.

Secondary outcome measures

1. Changes in serum levels of leukotrienes B5 and B4, Tumor Necrosis Factor alpha (TNF-a) and Interleukin 6 (IL-6). These are modulators of the inflammatory response
2. Measurements of omega-3 fatty acid levels and ratios in cellular membranes of blood leukocytes (white blood cells)
3. Change in vascular endothelial growth factor receptor levels
4. Changes in Cyclooxygenase-2 (COX-2) activity in patients white blood cells (an enzyme which inhibits cancer cell death)
5. Omega-3/omega-6 ratios in subjects platelets and resected tumour

Overall study start date

01/03/2006

Completion date

01/08/2006

Eligibility

Key inclusion criteria

Patients with hepatic colorectal metastases, in whom the disease is assessed as amenable to curative resection will be eligible for the study. The inclusion criteria will be:

1. Ages 18-80
2. Able to give informed written consent
3. Diagnosis of resectable hepatic colorectal metastases on radiological and laparoscopic appearance (this trial is only assessing operative disease)

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Upper age limit

80 Years

Sex

Both

Target number of participants

20

Key exclusion criteria

Patients will be excluded from this trial if they have:

1. Malignant disease that is not thought to be potentially operable after laparoscopy
2. Patients already taking fish oil supplements (may interfere with results)
3. Patients already enrolled into other trials (e.g. of chemotherapy)
4. Hypersensitivity to fish, egg or soy protein or to any of the active substances or constituents in the lipid emulsion
5. Hyperlipidaemia
6. Severe blood coagulation disorders
7. Severe renal insufficiency (creatinine >200)
8. Any general contra-indications to infusion therapy pulmonary oedema, hyperhydration, decompensated cardiac insufficiency
9. Any unstable medical conditions uncontrolled diabetes mellitus, acute myocardial infarction, stroke, embolic disease, metabolic acidosis, sepsis, pancreatitis

Patients meeting the above criteria are excluded as they represent inoperable disease, cases where the results would be invalid (already taking fish oil supplements), contraindications to lipid infusion and unstable medical conditions.

Patients will also be excluded if they have any contraindications to MRI scanning:

1. Cardiac pacemaker
2. Other ferromagnetic metal implants not authorised for use in MRI such as certain types of cerebral aneurysm clips
3. Claustrophobia
4. Body weight or circumference beyond the MRI scanners capacity

Date of first enrolment

01/03/2006

Date of final enrolment

01/08/2006

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Department of Surgery

Leicester

United Kingdom

LE5 4PW

Sponsor information

Organisation

University Hospitals of Leicester NHS trust (UK)

Sponsor details

University Hospitals of Leicester Trust Headquarters
Gwendolen House
Gwendolen Road
Leicester
England
United Kingdom
LE5 4PW

Sponsor type

Hospital/treatment centre

ROR

<https://ror.org/02fha3693>

Funder(s)

Funder type

Industry

Funder Name

BBraun Melsungen AC (Germany)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
-------------	---------	--------------	------------	----------------	-----------------

Results article	results	07/05/2013	Yes	No
Results article	results	01/06/2013	Yes	No